Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25410478 | 0.79 | NPC1 (0.41) | NPY5RPDE10ATRPV1RAB9AKMT2A | |
| SCHEMBL31435420 | 0.79 | NPC1 (0.41) | NPY5RPDE10ATRPV1RAB9AKMT2A | |
| SCHEMBL31435476 | 0.77 | ALOX15 (0.48) | TRPV1RAB9A | |
| SCHEMBL25407989 | 0.77 | ALOX15 (0.48) | TRPV1RAB9A | |
| SCHEMBL10331192 | 0.77 | CYP1A2 (0.52) | NPY5RRAB9ACYP1A2LMNAPOLB | |
| SCHEMBL2397429 | 0.77 | KDR (0.48) | TRPV1RAB9ACYP1A2LMNAPOLB | |
| SCHEMBL17974789 | 0.77 | PDE10A (0.50) | NPY5RPDE10ARAB9AKMT2ACYP1A2 | |
| SCHEMBL151560 | 0.74 | CYP1A2 (0.57) | PDE10ARAB9ACYP1A2LMNAPOLB | |
| SCHEMBL19480370 | 0.74 | PDE10A (0.50) | PDE10ARAB9AKMT2ACYP1A2 | |
| SCHEMBL7407470 | 0.74 | F2RL3 (0.47) | NPY5RRAB9AKMT2ACYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066627-B1 | NOVEL MINOR GROOVE BINDERS | UNIV STRATHCLYDE (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8012967-B2 | Minor groove binders | UNIVERSITY OF STRATHCLYDE (GB) | 2011-09-06 | — | — | US | disclosed |
| US-20100016311-A1 | NOVEL MINOR GROOVE BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2066627-A1 | NOVEL MINOR GROOVE BINDERS | The University of Strathclyde (GB) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008038018-A1 | NOVEL MINOR GROOVE BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016311-A1 | NOVEL MINOR GROOVE BINDERS | TOP2B, DNA2, CTCF | NPY5R 2961/4885PDE10A 1242/4885TRPV1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.